Spermatocytomas
Spermatocytomas, also known as spermatocytic seminomas, are a rare form of germ-cell-derived testicular cancer, accounting for 1 to 2 percent of all testicular tumors. These tumors primarily affect older men, typically between the ages of 45 and 80, and generally present as a painless swelling in one testicle. While the exact cause of spermatocytomas remains unknown, certain factors such as cryptorchidism (failure of the testes to descend) and a family history of testicular cancer may elevate risk. Notably, these tumors are characterized by their slow growth and are often confined to the testicle, with metastasis being extremely rare.
Diagnosis usually involves a physical examination, and advancements in medical imaging have improved detection rates. Surgical removal of the affected testicle, known as orchidectomy, is the common treatment method, and recent approaches have focused on preserving patient fertility. Prognosis is generally favorable, with five-year survival rates ranging from 80 to 100 percent following treatment. As research continues to explore the underlying genetic factors and molecular biology related to these tumors, a deeper understanding of spermatocytomas may emerge.
On this Page
Subject Terms
Spermatocytomas
ALSO KNOWN AS: Spermatocytic seminomas
RELATED CONDITIONS: Germ-cell tumors, seminomas
DEFINITION: Spermatocytomas are a type of rare, germ-cell-derived testicular cancer.
Risk factors: No definitive genetic mutations or lifestyle habits have been identified that correlate with increased risk for developing spermatocytoma. Cryptorchidism, failure of the testes to descend by the time a boy reaches school age, is associated with increased risk of testicular cancer, as is a family history of testicular cancer. There is some suggestion that the presence of environmental estrogens may be related to an increased incidence of testicular pathologies, including spermatocytoma, but there is no definitive evidence for this hypothesis. As medical researchers better understand the genetic make-up and molecular biology of germ-cell testicular tumors, they can gain a more completed understanding of genetic predispositions and biomarkers for spermatocytoma.
Etiology and the disease process: The etiology is unknown. Spermatocytomas do not appear to arise from the same precursor cells as other germ-cell-derived testicular cancers. Some data indicate that spermatogonia (early sperm precursor cells) may be the cells from which spermatocytoma is derived. Spermatocytoma has a soft gray appearance on gross examination, with cystic areas in the tumor that do not show any hemorrhaged or necrotic areas. Microscopically, the tumor consists of tubular clusters of round cells that are highly variable in size. These cells are characterized by small, intermediate, and large nuclear regions. These are extremely slow-growing tumors, and metastasis of these tumors has been reported only anecdotally.
Incidence: Spermatocytomas represent between 1 and 2 percent of all testicular tumors, and approximately 10 percent occur in both testicles. They occur in older men aged forty-five to eighty. One retrospective study of 200 cases reported a single metastasis.
Symptoms: These tumors generally manifest as a painless swelling in one testicle, although there are some reports of tenderness associated with the tumors.
Screening and diagnosis: This cancer is diagnosed by physical exam. Spermatocytoma is most often confined to one or both testes (Stage I). In Stage II, the cancer has spread to lymph nodes, and in Stage III, it has metastasized. There are no specific chromosomal aberrations of the germ line or genetic mutation linked to this cancer. There are no specific blood markers for these tumors, although high expression of the tumor-suppressor gene TP53 has been reported. Advances in medical imaging have made the diagnosis of spermatocytoma easier and more accurate.
Treatment and therapy: Spermatocytoma is rarely metastatic and is usually contained within the testicle. Most often, it is treated surgically by removing the affected testicle (orchidectomy). In the twenty-first century, advances have been made in preserving the fertility of patients undergoing treatment for spermatocytoma.
Prognosis, prevention, and outcomes: Since spermatocytoma is slow-growing and rarely metastatic, the prognosis is positive. Five-year survival rates of 80 to 100 percent have been reported after surgical treatment. In rare cases of metastasis, the survival rate is approximately 73 percent.
Bibliography
Linn, Emma, et al. "Genes Regulating Spermatogenesis and Sperm Function Associated With Rare Disorders." Frontiers in Cell and Developmental Biology, vol. 9, 2021, doi.org/10.3389/fcell.2021.634536. Accessed 26 June 2024.
Secondino, Simona, et al. "Testicular Tumors in the 'Elderly' Population." Frontiers in Oncology, vol. 12, 2022, doi.org/10.3389/fonc.2022.972151. Accessed 26 June 2024.
"Testicular Cancer." MedlinePlus, 29 Apr. 2022, medlineplus.gov/ency/article/001288.htm. Accessed 26 June 2024.
“Testicular Cancer Survival Rates - Testicular Cancer Prognosis.” American Cancer Society, 1 Mar. 2023, www.cancer.org/cancer/types/testicular-cancer/detection-diagnosis-staging/survival-rates.html. Accessed 26 June 2024.
“Testicular Cancer - Testicular Tumor.” American Cancer Society, www.cancer.org/cancer/types/testicular-cancer.html. Accessed 26 June 2024.
“Testicular Cancer Treatment.” National Cancer Institute, 17 May 2023, www.cancer.gov/types/testicular/patient/testicular-treatment-pdq. Accessed 26 June 2024.
Wang, Xiaoyan, et al. "When Spermatogenesis Meets Human Aging and Elevated Body Mass." Life Medicine, vol. 1, no. 3, 2022, pp. 267-269, doi.org/10.1093/lifemedi/lnac022. Accessed 26 June 2024.